NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Yes Securities Report
Symphony Ltd.'s on consolidated basis reported lower than expected revenue on back of subdued domestic sales. Lower off take was on account of high channel inventory of the cooling products resulting from the poor summer sales.
Gross margins have seen expansion on back of tactical pricing, value engineering and softening of commodity prices, higher gross margin has resulted in expansion in Ebitda margin. Subsidiaries on the other hand has seen 12% YoY revenue growth on back of strong summer tailwind in Mexico and Brazil and improving performance of CT Australia and GSK China.
Symphony expects off-take to improve in Q4 as advance collections continues to remain strong and inventory levels have normalised. Management has already started to implement its strategy to turnaround its international subsidiaries especially that of CT Australia, where they have will be moving to outsourced model versus In-house manufacturing, introduction of new product category and increasing offering in existing products.
We feel improvement in performance of CT Australia will be more gradual. Considering lower than expected demand in the domestic business and gradual improvement in international subsidiaries, we downgrade the stock to 'Add'. We will wait for improvement in domestic demand before we get positive on the stock.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU

What Do HCLTech's Q1 Result Numbers Say? Read Systematix Report


Sun Pharma, Cipla And More — Nirmal Bang's Top Stock Picks In Pharma Pack; Q1 Results Preview


TCS Q1 Results Review — 'Buy' The Stock Maintains Systematix On Robust Pipeline, Compelling Valuations


Explained: What Is 'Credit Hunger'? How It Affects Your Credit Score
